What Skyrizi's July TV Spend Means for Omnichannel Engagement
    Back to Blog
    Commercial Effectiveness

    What Skyrizi's July TV Spend Means for Omnichannel Engagement

    M
    Mohammad AshourResearch Lead, BioNixus Healthcare Market Research
    12 Jun 2026
    14 min
    United States
    SkyriziAbbVieImmunologyOmnichannelCommercial effectivenessBrand trackingDTC advertising
    Share:

    July pharma TV ad spend and impression share for AbbVie's Skyrizi, and what that pattern means for omnichannel engagement, HCP digital, and promotional ROI beyond impressions.

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    Why did July reporting focus on Skyrizi's pharma TV spend?
    Industry reporting described Skyrizi (risankizumab) national TV ad spend and impression share-of-voice in July, reflecting AbbVie's sustained DTC investment in immunology alongside HCP-facing promotion for psoriasis and expanding indications.
    What is omnichannel engagement in pharma?
    Omnichannel engagement coordinates TV, digital HCP channels, field force, medical (MSL), and patient support so each touchpoint reinforces the same clinical and access narrative, with measurement that links channel exposure to prescribing intent and volume, not impressions alone.
    How should immunology brands respond to a competitor's DTC surge?
    Teams should refresh brand tracking (awareness, prescribing intent, promotional equity by channel), audit message consistency across TV and digital, and identify whether share gaps reflect access, perception, or reach, not assume TV spend alone explains share movement.
    Can BioNixus help measure omnichannel promotional performance?
    Yes. BioNixus designs HCP brand tracking, channel-recall modules, and integrated analyses that juxtapose survey KPIs with secondary prescription data where available, scoped to immunology and commercial effectiveness programmes across the US, Europe, and MENA.
    Does high DTC spend guarantee market share gains?
    No. DTC can lift patient demand and brand salience, but formulary access, step-therapy rules, biosimilar pressure, and HCP preference often determine whether awareness converts to new starts. Tracking must separate intent from access-constrained prescribing.

    Expert Consultation

    Scope immunology brand tracking or omnichannel research

    BioNixus helps commercial and medical teams align channel mix, message testing, and wave-on-wave tracking with the decisions that follow a competitor's promotional surge.

    Request a commercial briefing
    M

    Research Author

    Mohammad Ashour

    Research Lead, BioNixus Healthcare Market Research

    Updated 15 Nov 2026

    Related Articles

    Planning research in United States?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.